NCT05142696 2026-03-17
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Novartis
Phase 1/2 Active not recruiting
Clinical Trials
22 trialsNCT07037758 2026-02-20
DeLLphi-311
Amgen
Phase 1 Recruiting
NCT07107490 2026-02-06
A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER
Chugai Pharmaceutical
Phase 1 Recruiting
NCT04699838 2026-01-02
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT05468489 2025-10-21
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Active not recruiting
NCT06016270 2025-09-05
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
STCube, Inc.
Phase 1/2 Terminated
NCT06897579 2025-04-11
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Recruiting
NCT06597513 2024-10-15
Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1/2 Not yet recruiting
NCT06323265 2024-03-27
A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Hebei Medical University Fourth Hospital
Recruiting
NCT00057837 2023-07-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT05055947 2022-01-25
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer
Hunan Province Tumor Hospital
Completed
NCT05001412 2021-08-12
Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC
Guangzhou Institute of Respiratory Disease
Phase 1 Unknown
NCT04790539 2021-03-10
a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2 Unknown
NCT04213937 2019-12-30
Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Unknown
NCT02011087 2018-07-05
Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy
Wake Forest University Health Sciences
Phase NA Terminated
NCT02194049 2018-01-09
Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
University of California, Davis
Phase 1 Completed
NCT02972320 2016-11-23
Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic
China Medical University, China
Phase 2 Unknown
NCT00118235 2014-06-17
Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00079040 2014-05-14
Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00544596 2014-04-02
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00028028 2013-02-28
CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00017251 2013-01-24
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1 Completed